Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Common Equity (2022 - 2025)

Neuraxis (NRXS) has disclosed Common Equity for 4 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 64.4% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, up 64.4% year-over-year, with the annual reading at $3.4 million for FY2025, 64.4% up from the prior year.
  • Common Equity hit $3.4 million in Q4 2025 for Neuraxis, up from $2.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $4.3 million in Q2 2025 to a low of -$10.0 million in Q2 2023.
  • Historically, Common Equity has averaged -$2.2 million across 4 years, with a median of -$1.8 million in 2024.
  • Biggest five-year swings in Common Equity: tumbled 186.26% in 2023 and later surged 247.36% in 2024.
  • Year by year, Common Equity stood at -$5.6 million in 2022, then soared by 74.82% to -$1.4 million in 2023, then soared by 247.36% to $2.1 million in 2024, then soared by 64.4% to $3.4 million in 2025.
  • Business Quant data shows Common Equity for NRXS at $3.4 million in Q4 2025, $2.3 million in Q3 2025, and $4.3 million in Q2 2025.